Imaging to track CAR-T cell therapy in multiple myeloma
Part of Blood & lymphatic, Cancer clinical trials.
This trial uses a special imaging agent (68Ga-NOTA-BCMA) to see where CAR-T cells go in your body. It aims to improve understanding of how well the therapy works. You must be planning to receive anti-BCMA CAR-T cell therapy for multiple myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma and are scheduled for anti-BCMA CAR-T cell therapy.
- You are able to undergo PET/CT scans (no claustrophobia or other issues).
- You are not pregnant or breastfeeding, and agree to use effective birth control for at least one year if needed.
- You do not have active hepatitis B, hepatitis C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This study tests a new CAR-T cell therapy that targets a protein called BCMA on myeloma cells. It is for patients with newly diagnosed multiple myeloma who cannot have a standard stem cell transplant. The therapy is a one-time infusion of your own immune cells that are modified to attack the cancer.
This study tests a new imaging agent that may help doctors see multiple myeloma more clearly. It uses a special radioactive tracer that targets a protein found on myeloma cells, which could improve diagnosis and monitoring of the disease.
Hear when a new Non-invasive CAR-T Cell Monitoring trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.